PE20130326A1 - Analogos de glucagon - Google Patents
Analogos de glucagonInfo
- Publication number
- PE20130326A1 PE20130326A1 PE2012002434A PE2012002434A PE20130326A1 PE 20130326 A1 PE20130326 A1 PE 20130326A1 PE 2012002434 A PE2012002434 A PE 2012002434A PE 2012002434 A PE2012002434 A PE 2012002434A PE 20130326 A1 PE20130326 A1 PE 20130326A1
- Authority
- PE
- Peru
- Prior art keywords
- ser
- leu
- lys
- tyr
- glu
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- -1 Ala Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A ANALOGOS DE GLUCAGON DE FORMULA R1-X-Z-R2 DONDE R1 ES H, ALQUILO(C1-C4), ACETILO, FORMILO, ENTRE OTROS; R2 ES OH O NH2; X ES UN PEPTIDO DE FORMULA His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-X16-X17-Arg-Ala-X20-Asp-Phe-Ile-Glu-Trp-Leu-X27-X28-X29 EN DONDE X2 ES Ser Y Aib; X16 ES Glu E Y; X17 ES Arg E Y; X20 ES Lys E Y; X27 ES Leu E Y; X28 ESTA AUSENTE O ES Ser E Y; X29 ESTA AUSENTE O ES Ala; Y ES Lys, Cys O Orn; Z ESTA AUSENTE O ES UNA SECUENCIA DE 1 A 20 UNIDADES DE AMINOACIDOS TALES COMO Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr Y Orn; EN DONDE LA CADENA LATERAL DE UN RESIDUO AMINOACIDICO Y DE X ESTA CONJUGADA CON UN SUSTITUYENTE LIPOFILO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE OBESIDAD, HIPERTENSION, ATEROESCLEROSIS, CARDIOPATIA CORONARIA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201000550 | 2010-06-23 | ||
| US35862310P | 2010-06-25 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130326A1 true PE20130326A1 (es) | 2013-03-17 |
Family
ID=44630045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002434A PE20130326A1 (es) | 2010-06-23 | 2011-06-23 | Analogos de glucagon |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9403894B2 (es) |
| EP (1) | EP2585481B1 (es) |
| JP (1) | JP5937582B2 (es) |
| KR (1) | KR20130086339A (es) |
| CN (1) | CN103038250A (es) |
| AP (1) | AP3286A (es) |
| AR (1) | AR081975A1 (es) |
| AU (1) | AU2011269427A1 (es) |
| BR (1) | BR112012033227A2 (es) |
| CA (1) | CA2802889A1 (es) |
| CL (1) | CL2012003643A1 (es) |
| CO (1) | CO6660484A2 (es) |
| EA (1) | EA201291233A1 (es) |
| EC (1) | ECSP12012351A (es) |
| MX (1) | MX2012014774A (es) |
| NZ (1) | NZ604033A (es) |
| PE (1) | PE20130326A1 (es) |
| PH (1) | PH12012502461A1 (es) |
| SG (1) | SG186276A1 (es) |
| TN (1) | TN2012000567A1 (es) |
| TW (1) | TW201202265A (es) |
| UY (1) | UY33462A (es) |
| WO (1) | WO2011160630A2 (es) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607150C (en) | 2005-05-04 | 2014-08-05 | Bjarne Due Larsen | Glucagon-like-peptide-2 (glp-2) analogues |
| WO2008056155A1 (en) | 2006-11-08 | 2008-05-15 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| EA020596B1 (ru) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MA34383B1 (fr) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | Analogues de glucagon |
| SG192038A1 (en) * | 2011-01-20 | 2013-08-30 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| EP2758426B1 (en) | 2011-09-23 | 2019-08-07 | Novo Nordisk A/S | Novel glucagon analogues |
| SG11201403377QA (en) * | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
| CN104540850B (zh) * | 2012-05-03 | 2018-05-18 | 西兰制药公司 | 胰高血糖素样肽2(glp-2)类似物 |
| EA201590011A1 (ru) | 2012-06-14 | 2015-05-29 | Санофи | Пептидные аналоги эксендина-4 |
| TWI642682B (zh) | 2012-07-23 | 2018-12-01 | 丹麥商西蘭製藥公司 | 升糖素類似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9546205B2 (en) | 2012-09-17 | 2017-01-17 | Imperial Innovations Limited | Peptide analogues of glucagon and GLP1 |
| GB2505941A (en) * | 2012-09-17 | 2014-03-19 | Imp Innovations Ltd | Peptide analogues of glucagon for the treatment of obesity and diabetes |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
| SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
| MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
| DK3057984T3 (en) | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| TWI670281B (zh) | 2013-11-06 | 2019-09-01 | 西蘭製藥公司 | Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法 |
| AU2014345570B2 (en) | 2013-11-06 | 2019-01-24 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐアゴニスト化合物及び方法 |
| EP3673900B1 (en) | 2015-02-17 | 2025-06-25 | Amphastar Pharmaceuticals, Inc. | Nasal powder formulation for treatment of hypoglycemia |
| CA2979950A1 (en) | 2015-03-18 | 2016-09-22 | Zealand Pharma A/S | Amylin analogues |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| RU2735762C2 (ru) | 2015-04-16 | 2020-11-06 | Зилэнд Фарма А/С | Ацилированный аналог глюкагона, его применение и способы получения |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| EP3468569A4 (en) | 2016-06-09 | 2020-05-27 | AmideBio LLC | GLUCAGON ANALOGS AND METHODS OF USING THE SAME |
| WO2018024653A1 (en) | 2016-08-05 | 2018-02-08 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
| JP6563614B1 (ja) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア／エス | アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| CN118526577A (zh) | 2017-06-16 | 2024-08-23 | 西兰制药公司 | 用于施用胰高血糖素样肽2（glp-2）类似物的剂量方案 |
| ES2973986T3 (es) * | 2017-08-16 | 2024-06-25 | Dong A St Co Ltd | Análogo peptídico acilado de oxintomodulina |
| BR112020014436A2 (pt) | 2018-02-02 | 2020-12-01 | Boehringer Ingelheim International Gmbh | derivados de triazolopirimidina, composição farmacêutica e seus usos como inibidores de grelina o-acil transferase (goat) |
| CA3087827A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| KR20200116978A (ko) | 2018-02-02 | 2020-10-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체 |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CA3096493A1 (en) * | 2018-04-10 | 2019-10-17 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
| BR112020020647A2 (pt) | 2018-04-10 | 2021-02-23 | Sanofi-Aventis Deutschland Gmbh | síntese de lixisenatida com capeamento |
| US20220153853A1 (en) | 2018-12-21 | 2022-05-19 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific protein |
| TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| CA3147770A1 (en) * | 2019-08-13 | 2021-02-18 | Jae Ha Ryu | Exenatide analog and use thereof |
| WO2021094259A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | Npy2 receptor agonists |
| ES2984466T3 (es) | 2020-05-22 | 2024-10-29 | Boehringer Ingelheim Int | Procedimiento de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
| CN115916789B (zh) | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| CN113292646B (zh) * | 2020-05-29 | 2022-05-13 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| WO1998011126A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| ES2294822T3 (es) | 1997-11-14 | 2008-04-01 | Amylin Pharmaceuticals, Inc. | Compuestos novedosos de agonistas de exendina. |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| JP3702181B2 (ja) | 1998-12-07 | 2005-10-05 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１の類似体 |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| SK2432004A3 (sk) | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Inzulínová zlúčenina s protrahovaným účinkom |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| AU2004234345A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| JP2008543816A (ja) | 2005-06-13 | 2008-12-04 | インペリアル イノベーションズ リミテッド | 新規化合物および該化合物が摂食行動に及ぼす効果 |
| WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| CN101534846B (zh) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | 显示生理学溶解性和稳定性的胰高血糖素类似物 |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| CN101622276B (zh) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| KR20100111683A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| KR20110021758A (ko) | 2008-04-22 | 2011-03-04 | 케이스 웨스턴 리저브 유니버시티 | 이형체-특이적 인슐린 유사체 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| CL2009001424A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. |
| AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| KR20110061552A (ko) | 2008-07-31 | 2011-06-09 | 케이스 웨스턴 리저브 유니버시티 | 할로겐 안정화된 인슐린 |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| CA2747155A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| WO2010070251A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| EA020596B1 (ru) * | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010080606A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Insulin analogs |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AU2011206979B2 (en) | 2010-01-20 | 2015-09-10 | Zealand Pharma A/S | Treatment of cardiac conditions |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MA34383B1 (fr) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | Analogues de glucagon |
| SG192038A1 (en) | 2011-01-20 | 2013-08-30 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| SG11201403377QA (en) | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| DK3057984T3 (en) | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
-
2011
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Withdrawn
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
-
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
-
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2585481B1 (en) | 2015-08-19 |
| WO2011160630A2 (en) | 2011-12-29 |
| UY33462A (es) | 2012-01-31 |
| NZ604033A (en) | 2014-12-24 |
| US9403894B2 (en) | 2016-08-02 |
| PH12012502461A1 (en) | 2013-02-18 |
| JP5937582B2 (ja) | 2016-06-22 |
| EA201291233A1 (ru) | 2013-07-30 |
| AP2013006669A0 (en) | 2013-01-31 |
| EP2585481A2 (en) | 2013-05-01 |
| TW201202265A (en) | 2012-01-16 |
| TN2012000567A1 (en) | 2014-04-01 |
| MX2012014774A (es) | 2013-01-29 |
| US20160304576A1 (en) | 2016-10-20 |
| WO2011160630A3 (en) | 2012-02-16 |
| KR20130086339A (ko) | 2013-08-01 |
| JP2013534919A (ja) | 2013-09-09 |
| AR081975A1 (es) | 2012-10-31 |
| CN103038250A (zh) | 2013-04-10 |
| AP3286A (en) | 2015-05-31 |
| US20130157935A1 (en) | 2013-06-20 |
| CL2012003643A1 (es) | 2013-08-02 |
| BR112012033227A2 (pt) | 2017-06-20 |
| CO6660484A2 (es) | 2013-04-30 |
| SG186276A1 (en) | 2013-01-30 |
| AU2011269427A1 (en) | 2012-12-20 |
| ECSP12012351A (es) | 2013-01-31 |
| CA2802889A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130326A1 (es) | Analogos de glucagon | |
| PE20130338A1 (es) | Analogos del glucagon | |
| PE20142113A1 (es) | Analogos de glucagon | |
| NZ597554A (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
| PE20160683A1 (es) | Analogos de glucagon acilados | |
| NZ597981A (en) | Acylated glucagon analogues | |
| MX2010004297A (es) | Antagonistas de glucagon. | |
| NZ589847A (en) | Glucagon/glp-1 receptor co-agonists | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| MX2010004298A (es) | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. | |
| PE20140186A1 (es) | Analogos de glucagon que presentan actividad de receptor de gip | |
| PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| PE20231639A1 (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1) | |
| AR091866A1 (es) | Analogos del glucagon | |
| WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
| AR081339A1 (es) | Conjugados peptidicos | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| AR088161A1 (es) | Analogos de glucagon | |
| PE20191083A1 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| PE20200678A1 (es) | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) | |
| CL2012002031A1 (es) | Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente. | |
| TN2009000313A1 (en) | Glucagon/glp - 1 receptor co-agonists | |
| AR067972A1 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer | |
| MY152979A (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| PE20140160A1 (es) | Polipeptidos de relaxina modificados y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |